Compare Adaptive Biotechnologies Corp (ADPT) vs Upwork Inc (UPWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Upwork Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Upwork Inc trades at $8.66 (market cap $1.10B). The key difference: Adaptive Biotechnologies Corp is far larger — about 3× Upwork Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | UPWK | |
|---|---|---|
Market Cap | $3.33B | $1.10B |
Sector | Health | Industrials |
52-Week High | $22.37 | $22.11 |
52-Week Low | $10.24 | $7.84 |
Enterprise Value | $3.19B | $895.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
UPWK trades at $8.87, down 3.17% today, with a bullish technical signal from moving averages and ADX indicators. The company reported $787.78M revenue in 2025 with a net income margin of 14.65%, though recent quarters show earnings misses. Positive developments include a new AI partnership with Claude announced June 17, 2026, while legal investigations into securities violations pose headwinds.
The stock presents a mixed outlook: valuation ratios like P/E of 10.94 and EV/EBITDA of 5.8 suggest potential upside to the $10.67 consensus target, but earnings volatility and legal risks require caution. Growth in the gig economy supports long-term opportunity, yet investor sentiment is tempered by recent guidance cuts and shareholder lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
